Company Overview and News

 
Trading ideas: Inta Bina, Zelan, Bumi Armada, Globaltec

2018-04-18 thestar.com.my
KUALA LUMPUR: Intan Bina Group Bhd, Zelan Bhd , Bumi Armada Bhd and Globaltec Formation Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
Upvote Downvote

 
Bursa turns lower at mid-morning

2017-09-28 themalaymailonline
Market breadth was negative with 329 decliners and 267 gainers, while 337 counters were unchanged, 935 untraded and 66 others suspended. — Reuters picKUALA LUMPUR, Sept 28 — Bursa Malaysia turned lower at mid-morning today on lack of buying interest.  
Upvote Downvote

 
Admission

2016-04-27 londonstockexchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBILC OF SOUTH AFRICA NOR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Upvote Downvote

 
 
 
Australia's NuEnergy Appoints Kee Yong Wah as Deputy Executive Chairman

2016-04-07 rigzone
NuEnergy Gas Ltd., a gas and ancillary power generation development firm focused on unconventional gas production in Indonesia, announced Thursday the appointment of Kee Yong Wah as deputy executive chairman of the company with effect from April 7.
Upvote Downvote

 
SKK Migas Extends Sumatra's Rengat PSC Exploration Period to November 2019

2016-02-01 rigzone
NuEnergy reveals that upstream regulator SKK Migas has extended the exploration period for the Rengat Production Sharing Contract in Sumatra, Indonesia to November 2019.
Upvote Downvote

 
 

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...